Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 5/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.38 |
| ▸ | ELANE | P08246 | 2/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | PLCG1 | P19174 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.38 |
| ▸ | SLC40A1 | Q9NP59 | 1/20 | 0.38 |
| ▸ | RECQL | P46063 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | USP2 | O75604 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18611 | 0.85 | LRRK2 (0.46) | LRRK2HPGDALDH1A1SMN1; SMN2ELANE | |
| SCHEMBL29533314 | 0.85 | LRRK2 (0.46) | LRRK2HPGDALDH1A1SMN1; SMN2ELANE | |
| SCHEMBL6385617 | 0.85 | TDP1 (0.33) | ALDH1A1SMN1; SMN2CYP3A4CYP2D6PLCG1 | |
| SCHEMBL3248902 | 0.83 | PLCG1 (0.41) | LRRK2HPGDALDH1A1SMN1; SMN2ELANE | |
| SCHEMBL12754871 | 0.79 | GRM5 (0.46) | LRRK2HPGDALDH1A1SMN1; SMN2ELANE | |
| Cyclohexane SCHEMBL507539 | 0.75 | GRM5 (0.43) | LRRK2HPGDALDH1A1SMN1; SMN2ELANE | |
| Pyrrole SCHEMBL28114401 | 0.75 | LRRK2 (0.42) | LRRK2HPGDALDH1A1SMN1; SMN2CYP1A2 | |
| SCHEMBL29489584 | 0.74 | — | — | |
| SCHEMBL647575 | 0.74 | — | — | |
| SCHEMBL155110 | 0.74 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2842944-B1 | METHOD FOR PRODUCING NITROGEN-CONTAINING HETEROCYCLIC COMPOUND | NIPPON SODA CO (JP) | 2017-03-15 | — | — | EP | disclosed |
| EP-2557078-B1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND AND METHOD FOR PRODUCING SAME | NIPPON SODA CO (JP) | 2016-03-23 | — | — | EP | disclosed |
| EP-2730561-B1 | Methods to prepare haloalkyl nitrogen-containing heterocyclic compounds | NIPPON SODA CO (JP) | 2015-10-14 | — | — | EP | disclosed |
| EP-2736907-B1 | INDAZOLES | PFIZER LTD (GB) | 2015-10-07 | — | — | EP | disclosed |
| US-8981107-B2 | Nitrogen-containing heterocyclic compound and method for producing same | NIPPON SODA CO., LTD. (JP) | 2015-03-17 | — | — | US | disclosed |
| EP-2842944-A1 | Method for producing nitrogen-containing heterocyclic compound | NIPPON SODA CO., LTD. (JP) | 2015-03-04 | — | — | EP | disclosed |
| US-8962849-B2 | Nitrogen-containing heterocyclic compound and method for producing same | NIPPON SODA CO., LTD. (JP) | 2015-02-24 | — | — | US | disclosed |
| US-8962850-B2 | Nitrogen-containing heterocyclic compound and method for producing same | NIPPON SODA CO., LTD. (JP) | 2015-02-24 | — | — | US | disclosed |
| US-8921380-B2 | Pyrazolo[1,5-a] pyrimidine compounds as CB1 receptor antagonist | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2014-12-30 | — | — | US | disclosed |
| US-8895544-B2 | Indazoles | PFIZER LIMITED (GB) | 2014-11-25 | — | — | US | disclosed |
| US-20090069298-A1 | Pyrazolo[1,5-A]Pyrimidine Compounds | TANABE SEIYAKU CO., LTD. (JP) | 2009-03-12 | — | — | US | disclosed |
| US-20090048256-A1 | Pyrazole Compounds Having Cannabinoid Receptor (CB1) Antagonizing Activity | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2009-02-19 | — | — | US | disclosed |
| EP-1951678-A1 | PYRAZOLE COMPOUNDS HAVING CANNABINOID RECEPTOR (CB1) ANTAGONIZING ACTIVITY | Mitsubishi Tanabe Pharma Corporation (JP) | 2008-08-06 | — | — | EP | disclosed |
| EP-1945220-A1 | PYRAZOLO[1,5-A]PYRIMIDINE COMPOUNDS AS CANNABINOID RECEPTOR ANTAGONISTS | Mitsubishi Tanabe Pharma Corporation (JP) | 2008-07-23 | — | — | EP | disclosed |
| WO-2008004698-A2 | PYRAZOLO [1, 5-A] PYRIMIDINE COMPOUNDS AS CB1 RECEPTOR ANTAGONIST | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2008-01-10 | — | — | WO | disclosed |
| WO-2007046548-A1 | PYRAZOLO[1,5-A]PYRIMIDINE COMPOUNDS AS CANNABINOID RECEPTOR ANTAGONISTS | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2007-04-26 | — | — | WO | disclosed |
| WO-2007046550-A1 | PYRAZOLE COMPOUNDS HAVING CANNABINOID RECEPTOR (CB1) ANTAGONIZING ACTIVITY | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2007-04-26 | — | — | WO | disclosed |
| US-5654322-A | HYPOTENSIVE AGENTS, CEREBRAL APOPLEXY | WAKUNAGA SEIYAKU KABUSHIKI KAISHA (JP) | 1997-08-05 | — | — | US | disclosed |
| EP-0656355-A1 | BIPHENYLMETHANE DERIVATIVE AND MEDICINE CONTAINING THE SAME | WAKUNAGA SEIYAKU KABUSHIKI KAISHA (JP) | 1995-06-07 | — | — | EP | disclosed |
| US-3941781-A | Preparation of 3-alkylthiomethyl cephalosporins | ELI LILLY AND COMPANY (US) | 1976-03-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090069298-A1 | Pyrazolo[1,5-A]Pyrimidine Compounds | RECQL, QTRT1, DPYD | LRRK2 2121/4885HPGD 1170/4885ALDH1A1 467/4885 |
| US-20090048256-A1 | Pyrazole Compounds Having Cannabinoid Receptor (CB1) Antagonizing Activity | CNR1, CNR2, OPRD1 | LRRK2 2645/4885HPGD 2035/4885ALDH1A1 1631/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.